{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:00:43Z","timestamp":1781139643949,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13381-9","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:46:26Z","timestamp":1777027586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a modified PAGE-B score based nomogram for predicting hepatocellular carcinoma in antiviral-treated chronic hepatitis B patients with metabolic dysfunction"],"prefix":"10.1186","volume":"26","author":[{"given":"Qian","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"6","key":"13381_CR1","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264\u201373.e1. https:\/\/doi.org\/10.1053\/j.gastro.2011.12.061.","journal-title":"Gastroenterology"},{"issue":"1","key":"13381_CR2","doi-asserted-by":"publisher","first-page":"102406","DOI":"10.1016\/j.jceh.2024.102406","volume":"15","author":"A Koshy","year":"2025","unstructured":"Koshy A. Evolving global etiology of hepatocellular carcinoma (HCC): insights and trends for 2024. J Clin Exp Hepatol. 2025;15(1):102406. https:\/\/doi.org\/10.1016\/j.jceh.2024.102406.","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"13381_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatol (Baltim Md). 2023;78(6):1966\u201386. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","journal-title":"Hepatol (Baltim Md.)"},{"key":"13381_CR4","doi-asserted-by":"publisher","first-page":"156080","DOI":"10.1016\/j.metabol.2024.156080","volume":"162","author":"A Armandi","year":"2025","unstructured":"Armandi A, Rosso C, Caviglia GP, Bugianesi E. An updated overview on hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic Liver disease: trends, pathophysiology and risk-based surveillance. Metab: Clin Exp. 2025;162:156080. https:\/\/doi.org\/10.1016\/j.metabol.2024.156080.","journal-title":"Metab: Clin Exp"},{"issue":"6","key":"13381_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/cancers16061114","volume":"16","author":"M Su\u00e1rez","year":"2024","unstructured":"Su\u00e1rez M, Gil-Rojas S, Mart\u00ednez-Blanco P, Torres AM, Ram\u00f3n A, Blasco-Segura P, et al. Machine learning-based assessment of survival and risk factors in non-alcoholic fatty liver disease-related hepatocellular carcinoma for optimized patient management. Cancers. 2024;16(6):1114. https:\/\/doi.org\/10.3390\/cancers16061114.","journal-title":"Cancers"},{"issue":"4","key":"13381_CR6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1053\/j.gastro.2017.07.001","volume":"153","author":"MW Yu","year":"2017","unstructured":"Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology. 2017;153(4):1006\u201317.e5. https:\/\/doi.org\/10.1053\/j.gastro.2017.07.001.","journal-title":"Gastroenterology"},{"issue":"5","key":"13381_CR7","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.jhepr.2021.100350","volume":"3","author":"LA van Kleef","year":"2021","unstructured":"van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep: Innov Hepatol. 2021;3(5):100350. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100350.","journal-title":"JHEP Rep: Innov Hepatol"},{"issue":"4","key":"13381_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","volume":"64","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in caucasians with chronic hepatitis B on 5-year antiviral therapy. J Educ Chang Hepatol. 2016;64(4):800\u201306. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.035.","journal-title":"J Educ Chang Hepatol"},{"issue":"5","key":"13381_CR9","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","volume":"69","author":"JH Kim","year":"2018","unstructured":"Kim JH, Kim YD, Lee M, Jun BG, Kim TS, Suk KT, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in asians with chronic hepatitis B on antiviral therapy. J Educ Chang Hepatol. 2018;69(5):1066\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2018.07.018.","journal-title":"J Educ Chang Hepatol"},{"issue":"1","key":"13381_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4.","journal-title":"Hepatol Int"},{"issue":"4","key":"13381_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia\u2013Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317\u201370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9.","journal-title":"Hepatol Int"},{"issue":"4","key":"13381_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","volume":"6","author":"LE Simental-Mend\u00eda","year":"2008","unstructured":"Simental-Mend\u00eda LE, Rodr\u00edguez-Mor\u00e1n M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299\u2013304. https:\/\/doi.org\/10.1089\/met.2008.0034.","journal-title":"Metab Syndr Relat Disord"},{"issue":"6","key":"13381_CR13","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","volume":"73","author":"R Fan","year":"2020","unstructured":"Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Educ Chang Hepatol. 2020;73(6):1368\u201378. https:\/\/doi.org\/10.1016\/j.jhep.2020.07.025.","journal-title":"J Educ Chang Hepatol"},{"issue":"8","key":"13381_CR14","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cells10081917","volume":"10","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S. Familiarity breeds strategy: In Silico untangling of the molecular complexity on course of autoimmune liver disease-to-hepatocellular carcinoma transition predicts novel transcriptional signatures. Cells. 2021;10(8):1917. https:\/\/doi.org\/10.3390\/cells10081917.","journal-title":"Cells"},{"issue":"5","key":"13381_CR15","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/microorganisms9050968","volume":"9","author":"JH Bockmann","year":"2021","unstructured":"Bockmann JH, Kohsar M, Murray JM, Hamed V, Dandri M, L\u00fcth S, et al. High rates of liver cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients with metabolic and cardiovascular comorbidities. Microorganisms. 2021;9(5):968. https:\/\/doi.org\/10.3390\/microorganisms9050968.","journal-title":"Microorganisms"},{"issue":"3","key":"13381_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3350\/cmh.2021.0281","volume":"28","author":"JH Yu","year":"2022","unstructured":"Yu JH, Cho SG, Jin YJ, Lee JW. The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection. Clin Mol Hepatol. 2022;28(3):351\u201361. https:\/\/doi.org\/10.3350\/cmh.2021.0281.","journal-title":"Clin Mol Hepatol"},{"key":"13381_CR17","doi-asserted-by":"publisher","first-page":"955287","DOI":"10.3389\/fpubh.2022.955287","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang J, Wang W, Li G. Development and validation of a risk prediction model for incident liver cancer. Front Public Health. 2022;10:955287. https:\/\/doi.org\/10.3389\/fpubh.2022.955287.","journal-title":"Front Public Health"},{"issue":"10","key":"13381_CR18","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","volume":"28","author":"VW-S Wong","year":"2010","unstructured":"Wong VW-S, Chan SL, Mo F, Chan TC, Loong HH-F, Wong GL-H, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. JCO. 2010;28(10):1660\u201365. https:\/\/doi.org\/10.1200\/JCO.2009.26.2675.","journal-title":"JCO"},{"issue":"12","key":"13381_CR19","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/liv.13450","volume":"37","author":"MN Kim","year":"2017","unstructured":"Kim MN, Hwang SG, Rim KS, Kim BK, Park JY, Kim DY, et al. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. Liver Int. 2017;37(12):1788\u201395. https:\/\/doi.org\/10.1111\/liv.13450.","journal-title":"Liver Int"},{"issue":"9","key":"13381_CR20","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/liv.14129","volume":"39","author":"HW Lee","year":"2019","unstructured":"Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, et al. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. Liver Int: Off J Int Assoc Study Liver. 2019;39(9):1624\u201330. https:\/\/doi.org\/10.1111\/liv.14129.","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"issue":"14","key":"13381_CR21","doi-asserted-by":"publisher","first-page":"11471","DOI":"10.3390\/ijms241411471","volume":"24","author":"M Kotsari","year":"2023","unstructured":"Kotsari M, Dimopoulou V, Koskinas J, Armakolas A. Immune system and hepatocellular carcinoma (HCC): new insights into HCC progression. IJMS. 2023;24(14):11471. https:\/\/doi.org\/10.3390\/ijms241411471.","journal-title":"IJMS"},{"issue":"1","key":"13381_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12935-020-1094-5","volume":"20","author":"J Zhao","year":"2020","unstructured":"Zhao J, Huang W, Wu Y, Luo Y, Wu B, Cheng J, et al. Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis. Cancer Cell Int. 2020;20(1):15. https:\/\/doi.org\/10.1186\/s12935-020-1094-5.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"13381_CR23","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1002\/cam4.5185","volume":"12","author":"CE Thomas","year":"2023","unstructured":"Thomas CE, Yu YC, Luu HN, Wang R, Paragomi P, Behari J, et al. Neutrophil-lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Cancer Med. 2023;12(3):3589\u2013600. https:\/\/doi.org\/10.1002\/cam4.5185.","journal-title":"Cancer Med"},{"issue":"2","key":"13381_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/cancers16020259","volume":"16","author":"AGS Phoolchund","year":"2024","unstructured":"Phoolchund AGS, Khakoo SI. MASLD and the development of HCC: pathogenesis and therapeutic challenges. Cancers. 2024;16(2):259. https:\/\/doi.org\/10.3390\/cancers16020259.","journal-title":"Cancers"},{"issue":"8","key":"13381_CR25","doi-asserted-by":"publisher","first-page":"102581","DOI":"10.1016\/j.dsx.2022.102581","volume":"16","author":"DL Tahapary","year":"2022","unstructured":"Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and Tryglyceride\/glucose index. Diabetes Metabolic Syndr: Clin Res Rev. 2022;16(8):102581. https:\/\/doi.org\/10.1016\/j.dsx.2022.102581.","journal-title":"Diabetes Metabolic Syndr: Clin Res Rev"},{"key":"13381_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2147\/JHC.S454037","volume":"11","author":"SH Yang","year":"2024","unstructured":"Yang SH, He YS, Zheng SQ, Zhang XJ, Dai H, Xue Y. Triglyceride-glucose index is an independent risk factor for hepatocellular carcinoma development in patients with HBV-related liver cirrhosis. JHC. 2024;11:737\u201346. https:\/\/doi.org\/10.2147\/JHC.S454037.","journal-title":"JHC"},{"issue":"17","key":"13381_CR27","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, lung, and blood institute scientific statement. Circulation. 2005;112(17):2735\u201352. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.169404.","journal-title":"Circulation"},{"issue":"3","key":"13381_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1172\/JCI10761","volume":"106","author":"MK Cavaghan","year":"2000","unstructured":"Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000;106(3):329\u201333. https:\/\/doi.org\/10.1172\/JCI10761.","journal-title":"J Clin Invest"},{"issue":"4","key":"13381_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ajg.2011.400","volume":"107","author":"DH Sinn","year":"2012","unstructured":"Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, Kim KM, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol. 2012;107(4):561\u201367. https:\/\/doi.org\/10.1038\/ajg.2011.400.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"13381_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/hep.21272","volume":"44","author":"CM Cantarini","year":"2006","unstructured":"Cantarini CM, de la Monte SM, Pang M, Tong M, D\u2019Errico A, Trevisani F, et al. Aspartyl-asparagyl \u03b2 hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatol (Baltim Md.). 2006;44(2):446\u201357. https:\/\/doi.org\/10.1002\/hep.21272.","journal-title":"Hepatol (Baltim Md.)"},{"issue":"3","key":"13381_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/hep.510260310","volume":"26","author":"S Tanaka","year":"1997","unstructured":"Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatol (Baltim Md.). 1997;26(3):598\u2013604. https:\/\/doi.org\/10.1002\/hep.510260310.","journal-title":"Hepatol (Baltim Md.)"},{"issue":"1","key":"13381_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatol (Baltim Md.). 2016;63(1):261\u201383. https:\/\/doi.org\/10.1002\/hep.28156.","journal-title":"Hepatol (Baltim Md.)"},{"issue":"2","key":"13381_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro B, Argemi J, Ronot M, Paradis V, Meyer T, Mazzaferro V, et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Educ Chang Hepatol. 2025;82(2):315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","journal-title":"J Educ Chang Hepatol"},{"issue":"2","key":"13381_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/apt.15867","volume":"52","author":"H Oh","year":"2020","unstructured":"Oh H, Jun DW, Lee IH, Ahn HJ, Kim BO, Jung S, et al. Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B. Aliment Pharmacol Ther. 2020;52(2):371\u201381. https:\/\/doi.org\/10.1111\/apt.15867.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13381-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13381-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13381-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:06:56Z","timestamp":1781136416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13381-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13381"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13381-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study complied with the principles of the Declaration of Helsinki and was approved by the Human Ethics Committee of Tianjin Second People\u2019s Hospital (Jin Er Ren Min Lun Shen Zi [2024] No. 69). According to the request of the Human Ethics Committee of Tianjin Second People\u2019s Hospital,this retrospective study does not involve the collection and publication of patient names and addresses and other privacy, so informed consent can be exempted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1107"}}